nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyldopa—COMT—breast cancer	0.465	1	CbGaD
Methyldopa—L-DOPA—Melphalan—breast cancer	0.257	1	CrCrCtD
Methyldopa—DDC—embryo—breast cancer	0.00209	0.0831	CbGeAlD
Methyldopa—COMT—nipple—breast cancer	0.00168	0.0666	CbGeAlD
Methyldopa—SLC15A1—epithelium—breast cancer	0.00127	0.0504	CbGeAlD
Methyldopa—DDC—female reproductive system—breast cancer	0.00127	0.0504	CbGeAlD
Methyldopa—DDC—adrenal gland—breast cancer	0.00124	0.0492	CbGeAlD
Methyldopa—SLC15A1—endometrium—breast cancer	0.00114	0.0452	CbGeAlD
Methyldopa—COMT—skin of body—breast cancer	0.00107	0.0426	CbGeAlD
Methyldopa—DDC—endocrine gland—breast cancer	0.00107	0.0426	CbGeAlD
Methyldopa—COMT—endometrium—breast cancer	0.00101	0.0402	CbGeAlD
Methyldopa—COMT—uterus—breast cancer	0.000933	0.0371	CbGeAlD
Methyldopa—COMT—pituitary gland—breast cancer	0.000916	0.0364	CbGeAlD
Methyldopa—COMT—adipose tissue—breast cancer	0.000912	0.0362	CbGeAlD
Methyldopa—ADRA2A—nipple—breast cancer	0.000854	0.0339	CbGeAlD
Methyldopa—COMT—female reproductive system—breast cancer	0.000838	0.0333	CbGeAlD
Methyldopa—COMT—adrenal gland—breast cancer	0.000818	0.0325	CbGeAlD
Methyldopa—SLC15A1—endocrine gland—breast cancer	0.000798	0.0317	CbGeAlD
Methyldopa—COMT—bone marrow—breast cancer	0.000792	0.0314	CbGeAlD
Methyldopa—COMT—female gonad—breast cancer	0.000763	0.0303	CbGeAlD
Methyldopa—DDC—lymph node—breast cancer	0.000742	0.0295	CbGeAlD
Methyldopa—COMT—endocrine gland—breast cancer	0.000709	0.0282	CbGeAlD
Methyldopa—ADRA2A—endometrium—breast cancer	0.000515	0.0205	CbGeAlD
Methyldopa—COMT—lymph node—breast cancer	0.00049	0.0195	CbGeAlD
Methyldopa—ADRA2A—uterus—breast cancer	0.000475	0.0189	CbGeAlD
Methyldopa—ADRA2A—pituitary gland—breast cancer	0.000466	0.0185	CbGeAlD
Methyldopa—ADRA2A—adipose tissue—breast cancer	0.000465	0.0185	CbGeAlD
Methyldopa—ADRA2A—female reproductive system—breast cancer	0.000427	0.017	CbGeAlD
Methyldopa—ADRA2A—adrenal gland—breast cancer	0.000417	0.0166	CbGeAlD
Methyldopa—ADRA2A—female gonad—breast cancer	0.000389	0.0154	CbGeAlD
Methyldopa—ADRA2A—endocrine gland—breast cancer	0.000361	0.0144	CbGeAlD
Methyldopa—Aminosalicylic Acid—PTGS1—breast cancer	0.000355	0.176	CrCbGaD
Methyldopa—Dopamine—COMT—breast cancer	0.000327	0.162	CrCbGaD
Methyldopa—Mesalazine—PTGS1—breast cancer	0.000278	0.138	CrCbGaD
Methyldopa—ADRA2A—lymph node—breast cancer	0.00025	0.00992	CbGeAlD
Methyldopa—Aminosalicylic Acid—PTGS2—breast cancer	0.000203	0.101	CrCbGaD
Methyldopa—Epinephrine—TNF—breast cancer	0.000193	0.0957	CrCbGaD
Methyldopa—Isoprenaline—CYP1A1—breast cancer	0.000175	0.0866	CrCbGaD
Methyldopa—Mesalazine—PTGS2—breast cancer	0.000159	0.079	CrCbGaD
Methyldopa—L-DOPA—CYP2D6—breast cancer	0.00012	0.0597	CrCbGaD
Methyldopa—Dopamine—CYP2D6—breast cancer	0.000112	0.0555	CrCbGaD
Methyldopa—Mental disorder—Docetaxel—breast cancer	9.59e-05	0.000545	CcSEcCtD
Methyldopa—Arthralgia—Paclitaxel—breast cancer	9.57e-05	0.000543	CcSEcCtD
Methyldopa—Myalgia—Paclitaxel—breast cancer	9.57e-05	0.000543	CcSEcCtD
Methyldopa—Mediastinal disorder—Capecitabine—breast cancer	9.55e-05	0.000542	CcSEcCtD
Methyldopa—Headache—Goserelin—breast cancer	9.54e-05	0.000542	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—breast cancer	9.51e-05	0.00054	CcSEcCtD
Methyldopa—Nausea—Tamoxifen—breast cancer	9.47e-05	0.000538	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Gemcitabine—breast cancer	9.46e-05	0.000537	CcSEcCtD
Methyldopa—Constipation—Gemcitabine—breast cancer	9.37e-05	0.000532	CcSEcCtD
Methyldopa—Pancytopenia—Methotrexate—breast cancer	9.36e-05	0.000532	CcSEcCtD
Methyldopa—Epinephrine—CYP3A4—breast cancer	9.36e-05	0.0464	CrCbGaD
Methyldopa—Asthenia—Thiotepa—breast cancer	9.35e-05	0.000531	CcSEcCtD
Methyldopa—Diarrhoea—Vinorelbine—breast cancer	9.33e-05	0.00053	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Fluorouracil—breast cancer	9.3e-05	0.000528	CcSEcCtD
Methyldopa—Abdominal distension—Epirubicin—breast cancer	9.29e-05	0.000527	CcSEcCtD
Methyldopa—Mental disorder—Capecitabine—breast cancer	9.29e-05	0.000527	CcSEcCtD
Methyldopa—Nausea—Melphalan—breast cancer	9.28e-05	0.000527	CcSEcCtD
Methyldopa—Oedema—Paclitaxel—breast cancer	9.18e-05	0.000521	CcSEcCtD
Methyldopa—Eosinophilia—Epirubicin—breast cancer	9.13e-05	0.000519	CcSEcCtD
Methyldopa—Liver function test abnormal—Doxorubicin—breast cancer	9.12e-05	0.000518	CcSEcCtD
Methyldopa—Infection—Paclitaxel—breast cancer	9.12e-05	0.000518	CcSEcCtD
Methyldopa—Flatulence—Capecitabine—breast cancer	9.09e-05	0.000516	CcSEcCtD
Methyldopa—Erectile dysfunction—Methotrexate—breast cancer	9.08e-05	0.000515	CcSEcCtD
Methyldopa—Nausea—Goserelin—breast cancer	9.05e-05	0.000514	CcSEcCtD
Methyldopa—Pancreatitis—Epirubicin—breast cancer	9.05e-05	0.000514	CcSEcCtD
Methyldopa—Dizziness—Vinorelbine—breast cancer	9.02e-05	0.000512	CcSEcCtD
Methyldopa—Orthostatic hypotension—Doxorubicin—breast cancer	9.02e-05	0.000512	CcSEcCtD
Methyldopa—Nervous system disorder—Paclitaxel—breast cancer	9e-05	0.000511	CcSEcCtD
Methyldopa—Angina pectoris—Epirubicin—breast cancer	8.99e-05	0.00051	CcSEcCtD
Methyldopa—Thrombocytopenia—Paclitaxel—breast cancer	8.98e-05	0.00051	CcSEcCtD
Methyldopa—Breast disorder—Doxorubicin—breast cancer	8.93e-05	0.000507	CcSEcCtD
Methyldopa—Diarrhoea—Thiotepa—breast cancer	8.91e-05	0.000506	CcSEcCtD
Methyldopa—Skin disorder—Paclitaxel—breast cancer	8.91e-05	0.000506	CcSEcCtD
Methyldopa—Body temperature increased—Mitoxantrone—breast cancer	8.89e-05	0.000505	CcSEcCtD
Methyldopa—Body temperature increased—Irinotecan—breast cancer	8.89e-05	0.000505	CcSEcCtD
Methyldopa—Toxic epidermal necrolysis—Doxorubicin—breast cancer	8.89e-05	0.000505	CcSEcCtD
Methyldopa—Infestation—Methotrexate—breast cancer	8.79e-05	0.000499	CcSEcCtD
Methyldopa—Infestation NOS—Methotrexate—breast cancer	8.79e-05	0.000499	CcSEcCtD
Methyldopa—Pancytopenia—Epirubicin—breast cancer	8.76e-05	0.000497	CcSEcCtD
Methyldopa—Vomiting—Vinorelbine—breast cancer	8.67e-05	0.000492	CcSEcCtD
Methyldopa—Body temperature increased—Gemcitabine—breast cancer	8.66e-05	0.000492	CcSEcCtD
Methyldopa—Dizziness—Thiotepa—breast cancer	8.62e-05	0.000489	CcSEcCtD
Methyldopa—Rash—Vinorelbine—breast cancer	8.6e-05	0.000488	CcSEcCtD
Methyldopa—Dermatitis—Vinorelbine—breast cancer	8.59e-05	0.000488	CcSEcCtD
Methyldopa—Abdominal distension—Doxorubicin—breast cancer	8.59e-05	0.000488	CcSEcCtD
Methyldopa—Headache—Vinorelbine—breast cancer	8.55e-05	0.000485	CcSEcCtD
Methyldopa—Leukopenia—Docetaxel—breast cancer	8.53e-05	0.000484	CcSEcCtD
Methyldopa—Body temperature increased—Fluorouracil—breast cancer	8.52e-05	0.000484	CcSEcCtD
Methyldopa—Eosinophilia—Doxorubicin—breast cancer	8.45e-05	0.00048	CcSEcCtD
Methyldopa—Weight increased—Epirubicin—breast cancer	8.4e-05	0.000477	CcSEcCtD
Methyldopa—Pancreatitis—Doxorubicin—breast cancer	8.37e-05	0.000475	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Paclitaxel—breast cancer	8.36e-05	0.000475	CcSEcCtD
Methyldopa—Angina pectoris—Doxorubicin—breast cancer	8.32e-05	0.000472	CcSEcCtD
Methyldopa—Hepatobiliary disease—Methotrexate—breast cancer	8.31e-05	0.000472	CcSEcCtD
Methyldopa—Hypersensitivity—Irinotecan—breast cancer	8.29e-05	0.000471	CcSEcCtD
Methyldopa—Hypersensitivity—Mitoxantrone—breast cancer	8.29e-05	0.000471	CcSEcCtD
Methyldopa—Vomiting—Thiotepa—breast cancer	8.28e-05	0.00047	CcSEcCtD
Methyldopa—Leukopenia—Capecitabine—breast cancer	8.26e-05	0.000469	CcSEcCtD
Methyldopa—Paraesthesia—Paclitaxel—breast cancer	8.24e-05	0.000468	CcSEcCtD
Methyldopa—Infestation NOS—Epirubicin—breast cancer	8.23e-05	0.000467	CcSEcCtD
Methyldopa—Infestation—Epirubicin—breast cancer	8.23e-05	0.000467	CcSEcCtD
Methyldopa—Rash—Thiotepa—breast cancer	8.22e-05	0.000466	CcSEcCtD
Methyldopa—Dermatitis—Thiotepa—breast cancer	8.21e-05	0.000466	CcSEcCtD
Methyldopa—Agranulocytosis—Methotrexate—breast cancer	8.2e-05	0.000466	CcSEcCtD
Methyldopa—Headache—Thiotepa—breast cancer	8.16e-05	0.000463	CcSEcCtD
Methyldopa—Myalgia—Docetaxel—breast cancer	8.11e-05	0.000461	CcSEcCtD
Methyldopa—Arthralgia—Docetaxel—breast cancer	8.11e-05	0.000461	CcSEcCtD
Methyldopa—Pancytopenia—Doxorubicin—breast cancer	8.11e-05	0.00046	CcSEcCtD
Methyldopa—Nausea—Vinorelbine—breast cancer	8.1e-05	0.00046	CcSEcCtD
Methyldopa—Asthenia—Mitoxantrone—breast cancer	8.07e-05	0.000458	CcSEcCtD
Methyldopa—Asthenia—Irinotecan—breast cancer	8.07e-05	0.000458	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—breast cancer	8.06e-05	0.000457	CcSEcCtD
Methyldopa—Jaundice—Epirubicin—breast cancer	8.02e-05	0.000455	CcSEcCtD
Methyldopa—Hypersensitivity—Fluorouracil—breast cancer	7.94e-05	0.000451	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Paclitaxel—breast cancer	7.92e-05	0.00045	CcSEcCtD
Methyldopa—Hepatitis—Methotrexate—breast cancer	7.89e-05	0.000448	CcSEcCtD
Methyldopa—Asthenia—Gemcitabine—breast cancer	7.86e-05	0.000446	CcSEcCtD
Methyldopa—Arthralgia—Capecitabine—breast cancer	7.86e-05	0.000446	CcSEcCtD
Methyldopa—Myalgia—Capecitabine—breast cancer	7.86e-05	0.000446	CcSEcCtD
Methyldopa—Constipation—Paclitaxel—breast cancer	7.85e-05	0.000446	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—breast cancer	7.8e-05	0.000443	CcSEcCtD
Methyldopa—Hepatobiliary disease—Epirubicin—breast cancer	7.78e-05	0.000442	CcSEcCtD
Methyldopa—Oedema—Docetaxel—breast cancer	7.78e-05	0.000442	CcSEcCtD
Methyldopa—Weight increased—Doxorubicin—breast cancer	7.77e-05	0.000441	CcSEcCtD
Methyldopa—Nausea—Thiotepa—breast cancer	7.74e-05	0.000439	CcSEcCtD
Methyldopa—Infection—Docetaxel—breast cancer	7.73e-05	0.000439	CcSEcCtD
Methyldopa—Diarrhoea—Irinotecan—breast cancer	7.7e-05	0.000437	CcSEcCtD
Methyldopa—Diarrhoea—Mitoxantrone—breast cancer	7.7e-05	0.000437	CcSEcCtD
Methyldopa—Agranulocytosis—Epirubicin—breast cancer	7.68e-05	0.000436	CcSEcCtD
Methyldopa—Nervous system disorder—Docetaxel—breast cancer	7.63e-05	0.000433	CcSEcCtD
Methyldopa—Thrombocytopenia—Docetaxel—breast cancer	7.62e-05	0.000432	CcSEcCtD
Methyldopa—Infestation—Doxorubicin—breast cancer	7.61e-05	0.000432	CcSEcCtD
Methyldopa—Infestation NOS—Doxorubicin—breast cancer	7.61e-05	0.000432	CcSEcCtD
Methyldopa—Skin disorder—Docetaxel—breast cancer	7.56e-05	0.000429	CcSEcCtD
Methyldopa—Oedema—Capecitabine—breast cancer	7.53e-05	0.000428	CcSEcCtD
Methyldopa—Bradycardia—Epirubicin—breast cancer	7.52e-05	0.000427	CcSEcCtD
Methyldopa—Diarrhoea—Gemcitabine—breast cancer	7.5e-05	0.000426	CcSEcCtD
Methyldopa—Infection—Capecitabine—breast cancer	7.48e-05	0.000425	CcSEcCtD
Methyldopa—Dizziness—Irinotecan—breast cancer	7.44e-05	0.000422	CcSEcCtD
Methyldopa—Jaundice—Doxorubicin—breast cancer	7.42e-05	0.000421	CcSEcCtD
Methyldopa—Nervous system disorder—Capecitabine—breast cancer	7.39e-05	0.000419	CcSEcCtD
Methyldopa—Hepatitis—Epirubicin—breast cancer	7.38e-05	0.000419	CcSEcCtD
Methyldopa—Diarrhoea—Fluorouracil—breast cancer	7.37e-05	0.000419	CcSEcCtD
Methyldopa—Thrombocytopenia—Capecitabine—breast cancer	7.37e-05	0.000419	CcSEcCtD
Methyldopa—Cardiac disorder—Methotrexate—breast cancer	7.32e-05	0.000416	CcSEcCtD
Methyldopa—Skin disorder—Capecitabine—breast cancer	7.31e-05	0.000415	CcSEcCtD
Methyldopa—Connective tissue disorder—Epirubicin—breast cancer	7.26e-05	0.000412	CcSEcCtD
Methyldopa—Body temperature increased—Paclitaxel—breast cancer	7.25e-05	0.000412	CcSEcCtD
Methyldopa—Hepatobiliary disease—Doxorubicin—breast cancer	7.2e-05	0.000409	CcSEcCtD
Methyldopa—Angiopathy—Methotrexate—breast cancer	7.16e-05	0.000406	CcSEcCtD
Methyldopa—Vomiting—Irinotecan—breast cancer	7.15e-05	0.000406	CcSEcCtD
Methyldopa—Vomiting—Mitoxantrone—breast cancer	7.15e-05	0.000406	CcSEcCtD
Methyldopa—Dizziness—Fluorouracil—breast cancer	7.13e-05	0.000405	CcSEcCtD
Methyldopa—Mediastinal disorder—Methotrexate—breast cancer	7.11e-05	0.000404	CcSEcCtD
Methyldopa—Agranulocytosis—Doxorubicin—breast cancer	7.1e-05	0.000403	CcSEcCtD
Methyldopa—Rash—Mitoxantrone—breast cancer	7.09e-05	0.000403	CcSEcCtD
Methyldopa—Rash—Irinotecan—breast cancer	7.09e-05	0.000403	CcSEcCtD
Methyldopa—Dermatitis—Mitoxantrone—breast cancer	7.09e-05	0.000402	CcSEcCtD
Methyldopa—Dermatitis—Irinotecan—breast cancer	7.09e-05	0.000402	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Docetaxel—breast cancer	7.09e-05	0.000402	CcSEcCtD
Methyldopa—Headache—Mitoxantrone—breast cancer	7.05e-05	0.0004	CcSEcCtD
Methyldopa—Headache—Irinotecan—breast cancer	7.05e-05	0.0004	CcSEcCtD
Methyldopa—Paraesthesia—Docetaxel—breast cancer	6.98e-05	0.000397	CcSEcCtD
Methyldopa—Vomiting—Gemcitabine—breast cancer	6.97e-05	0.000396	CcSEcCtD
Methyldopa—Bradycardia—Doxorubicin—breast cancer	6.96e-05	0.000395	CcSEcCtD
Methyldopa—Mental disorder—Methotrexate—breast cancer	6.91e-05	0.000392	CcSEcCtD
Methyldopa—Rash—Gemcitabine—breast cancer	6.91e-05	0.000392	CcSEcCtD
Methyldopa—Dermatitis—Gemcitabine—breast cancer	6.9e-05	0.000392	CcSEcCtD
Methyldopa—Headache—Gemcitabine—breast cancer	6.87e-05	0.00039	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Capecitabine—breast cancer	6.86e-05	0.00039	CcSEcCtD
Methyldopa—Cardiac disorder—Epirubicin—breast cancer	6.85e-05	0.000389	CcSEcCtD
Methyldopa—Vomiting—Fluorouracil—breast cancer	6.85e-05	0.000389	CcSEcCtD
Methyldopa—Hepatitis—Doxorubicin—breast cancer	6.83e-05	0.000388	CcSEcCtD
Methyldopa—Rash—Fluorouracil—breast cancer	6.79e-05	0.000386	CcSEcCtD
Methyldopa—Dermatitis—Fluorouracil—breast cancer	6.79e-05	0.000385	CcSEcCtD
Methyldopa—Paraesthesia—Capecitabine—breast cancer	6.76e-05	0.000384	CcSEcCtD
Methyldopa—Hypersensitivity—Paclitaxel—breast cancer	6.76e-05	0.000384	CcSEcCtD
Methyldopa—Headache—Fluorouracil—breast cancer	6.75e-05	0.000383	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Docetaxel—breast cancer	6.72e-05	0.000381	CcSEcCtD
Methyldopa—Connective tissue disorder—Doxorubicin—breast cancer	6.71e-05	0.000381	CcSEcCtD
Methyldopa—Angiopathy—Epirubicin—breast cancer	6.7e-05	0.00038	CcSEcCtD
Methyldopa—Nausea—Irinotecan—breast cancer	6.68e-05	0.000379	CcSEcCtD
Methyldopa—Nausea—Mitoxantrone—breast cancer	6.68e-05	0.000379	CcSEcCtD
Methyldopa—Mediastinal disorder—Epirubicin—breast cancer	6.66e-05	0.000378	CcSEcCtD
Methyldopa—Constipation—Docetaxel—breast cancer	6.65e-05	0.000378	CcSEcCtD
Methyldopa—Asthenia—Paclitaxel—breast cancer	6.58e-05	0.000374	CcSEcCtD
Methyldopa—Nausea—Gemcitabine—breast cancer	6.51e-05	0.00037	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Capecitabine—breast cancer	6.5e-05	0.000369	CcSEcCtD
Methyldopa—Mental disorder—Epirubicin—breast cancer	6.47e-05	0.000367	CcSEcCtD
Methyldopa—Constipation—Capecitabine—breast cancer	6.44e-05	0.000366	CcSEcCtD
Methyldopa—Nausea—Fluorouracil—breast cancer	6.4e-05	0.000363	CcSEcCtD
Methyldopa—Cardiac disorder—Doxorubicin—breast cancer	6.34e-05	0.00036	CcSEcCtD
Methyldopa—Flatulence—Epirubicin—breast cancer	6.33e-05	0.00036	CcSEcCtD
Methyldopa—Diarrhoea—Paclitaxel—breast cancer	6.28e-05	0.000356	CcSEcCtD
Methyldopa—Angiopathy—Doxorubicin—breast cancer	6.2e-05	0.000352	CcSEcCtD
Methyldopa—Mediastinal disorder—Doxorubicin—breast cancer	6.16e-05	0.00035	CcSEcCtD
Methyldopa—Body temperature increased—Docetaxel—breast cancer	6.15e-05	0.000349	CcSEcCtD
Methyldopa—Leukopenia—Methotrexate—breast cancer	6.15e-05	0.000349	CcSEcCtD
Methyldopa—Dizziness—Paclitaxel—breast cancer	6.07e-05	0.000345	CcSEcCtD
Methyldopa—Mental disorder—Doxorubicin—breast cancer	5.99e-05	0.00034	CcSEcCtD
Methyldopa—Body temperature increased—Capecitabine—breast cancer	5.95e-05	0.000338	CcSEcCtD
Methyldopa—Flatulence—Doxorubicin—breast cancer	5.86e-05	0.000333	CcSEcCtD
Methyldopa—Arthralgia—Methotrexate—breast cancer	5.85e-05	0.000332	CcSEcCtD
Methyldopa—Myalgia—Methotrexate—breast cancer	5.85e-05	0.000332	CcSEcCtD
Methyldopa—Vomiting—Paclitaxel—breast cancer	5.83e-05	0.000331	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	5.81e-05	0.00033	CcSEcCtD
Methyldopa—Rash—Paclitaxel—breast cancer	5.79e-05	0.000328	CcSEcCtD
Methyldopa—Dermatitis—Paclitaxel—breast cancer	5.78e-05	0.000328	CcSEcCtD
Methyldopa—Leukopenia—Epirubicin—breast cancer	5.75e-05	0.000327	CcSEcCtD
Methyldopa—Headache—Paclitaxel—breast cancer	5.75e-05	0.000326	CcSEcCtD
Methyldopa—Hypersensitivity—Docetaxel—breast cancer	5.73e-05	0.000325	CcSEcCtD
Methyldopa—Asthenia—Docetaxel—breast cancer	5.58e-05	0.000317	CcSEcCtD
Methyldopa—Infection—Methotrexate—breast cancer	5.57e-05	0.000316	CcSEcCtD
Methyldopa—Hypersensitivity—Capecitabine—breast cancer	5.55e-05	0.000315	CcSEcCtD
Methyldopa—Nervous system disorder—Methotrexate—breast cancer	5.5e-05	0.000312	CcSEcCtD
Methyldopa—Thrombocytopenia—Methotrexate—breast cancer	5.49e-05	0.000312	CcSEcCtD
Methyldopa—Myalgia—Epirubicin—breast cancer	5.47e-05	0.000311	CcSEcCtD
Methyldopa—Arthralgia—Epirubicin—breast cancer	5.47e-05	0.000311	CcSEcCtD
Methyldopa—Nausea—Paclitaxel—breast cancer	5.45e-05	0.000309	CcSEcCtD
Methyldopa—Skin disorder—Methotrexate—breast cancer	5.45e-05	0.000309	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	5.44e-05	0.000309	CcSEcCtD
Methyldopa—Asthenia—Capecitabine—breast cancer	5.4e-05	0.000307	CcSEcCtD
Methyldopa—Leukopenia—Doxorubicin—breast cancer	5.32e-05	0.000302	CcSEcCtD
Methyldopa—Diarrhoea—Docetaxel—breast cancer	5.32e-05	0.000302	CcSEcCtD
Methyldopa—Oedema—Epirubicin—breast cancer	5.25e-05	0.000298	CcSEcCtD
Methyldopa—Infection—Epirubicin—breast cancer	5.21e-05	0.000296	CcSEcCtD
Methyldopa—Diarrhoea—Capecitabine—breast cancer	5.15e-05	0.000293	CcSEcCtD
Methyldopa—Nervous system disorder—Epirubicin—breast cancer	5.14e-05	0.000292	CcSEcCtD
Methyldopa—Dizziness—Docetaxel—breast cancer	5.14e-05	0.000292	CcSEcCtD
Methyldopa—Thrombocytopenia—Epirubicin—breast cancer	5.14e-05	0.000292	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Methotrexate—breast cancer	5.11e-05	0.00029	CcSEcCtD
Methyldopa—Skin disorder—Epirubicin—breast cancer	5.1e-05	0.000289	CcSEcCtD
Methyldopa—Arthralgia—Doxorubicin—breast cancer	5.06e-05	0.000287	CcSEcCtD
Methyldopa—Myalgia—Doxorubicin—breast cancer	5.06e-05	0.000287	CcSEcCtD
Methyldopa—Paraesthesia—Methotrexate—breast cancer	5.03e-05	0.000286	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	5.03e-05	0.000286	CcSEcCtD
Methyldopa—Dizziness—Capecitabine—breast cancer	4.98e-05	0.000283	CcSEcCtD
Methyldopa—Vomiting—Docetaxel—breast cancer	4.95e-05	0.000281	CcSEcCtD
Methyldopa—Rash—Docetaxel—breast cancer	4.9e-05	0.000278	CcSEcCtD
Methyldopa—Dermatitis—Docetaxel—breast cancer	4.9e-05	0.000278	CcSEcCtD
Methyldopa—Headache—Docetaxel—breast cancer	4.87e-05	0.000277	CcSEcCtD
Methyldopa—Oedema—Doxorubicin—breast cancer	4.85e-05	0.000276	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Methotrexate—breast cancer	4.84e-05	0.000275	CcSEcCtD
Methyldopa—Infection—Doxorubicin—breast cancer	4.82e-05	0.000274	CcSEcCtD
Methyldopa—Vomiting—Capecitabine—breast cancer	4.79e-05	0.000272	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Epirubicin—breast cancer	4.78e-05	0.000271	CcSEcCtD
Methyldopa—Nervous system disorder—Doxorubicin—breast cancer	4.76e-05	0.00027	CcSEcCtD
Methyldopa—Thrombocytopenia—Doxorubicin—breast cancer	4.75e-05	0.00027	CcSEcCtD
Methyldopa—Rash—Capecitabine—breast cancer	4.75e-05	0.00027	CcSEcCtD
Methyldopa—Dermatitis—Capecitabine—breast cancer	4.74e-05	0.000269	CcSEcCtD
Methyldopa—Headache—Capecitabine—breast cancer	4.72e-05	0.000268	CcSEcCtD
Methyldopa—Skin disorder—Doxorubicin—breast cancer	4.72e-05	0.000268	CcSEcCtD
Methyldopa—Paraesthesia—Epirubicin—breast cancer	4.71e-05	0.000267	CcSEcCtD
Methyldopa—Nausea—Docetaxel—breast cancer	4.62e-05	0.000262	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Epirubicin—breast cancer	4.53e-05	0.000257	CcSEcCtD
Methyldopa—Constipation—Epirubicin—breast cancer	4.49e-05	0.000255	CcSEcCtD
Methyldopa—Nausea—Capecitabine—breast cancer	4.47e-05	0.000254	CcSEcCtD
Methyldopa—Body temperature increased—Methotrexate—breast cancer	4.43e-05	0.000252	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Doxorubicin—breast cancer	4.42e-05	0.000251	CcSEcCtD
Methyldopa—Paraesthesia—Doxorubicin—breast cancer	4.36e-05	0.000247	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Doxorubicin—breast cancer	4.19e-05	0.000238	CcSEcCtD
Methyldopa—Constipation—Doxorubicin—breast cancer	4.15e-05	0.000236	CcSEcCtD
Methyldopa—Body temperature increased—Epirubicin—breast cancer	4.15e-05	0.000235	CcSEcCtD
Methyldopa—Hypersensitivity—Methotrexate—breast cancer	4.13e-05	0.000234	CcSEcCtD
Methyldopa—Asthenia—Methotrexate—breast cancer	4.02e-05	0.000228	CcSEcCtD
Methyldopa—Hypersensitivity—Epirubicin—breast cancer	3.87e-05	0.000219	CcSEcCtD
Methyldopa—Body temperature increased—Doxorubicin—breast cancer	3.84e-05	0.000218	CcSEcCtD
Methyldopa—Diarrhoea—Methotrexate—breast cancer	3.84e-05	0.000218	CcSEcCtD
Methyldopa—Asthenia—Epirubicin—breast cancer	3.76e-05	0.000214	CcSEcCtD
Methyldopa—Dizziness—Methotrexate—breast cancer	3.71e-05	0.00021	CcSEcCtD
Methyldopa—Diarrhoea—Epirubicin—breast cancer	3.59e-05	0.000204	CcSEcCtD
Methyldopa—Hypersensitivity—Doxorubicin—breast cancer	3.58e-05	0.000203	CcSEcCtD
Methyldopa—Vomiting—Methotrexate—breast cancer	3.56e-05	0.000202	CcSEcCtD
Methyldopa—Rash—Methotrexate—breast cancer	3.53e-05	0.000201	CcSEcCtD
Methyldopa—Dermatitis—Methotrexate—breast cancer	3.53e-05	0.0002	CcSEcCtD
Methyldopa—Headache—Methotrexate—breast cancer	3.51e-05	0.000199	CcSEcCtD
Methyldopa—Asthenia—Doxorubicin—breast cancer	3.48e-05	0.000198	CcSEcCtD
Methyldopa—Dizziness—Epirubicin—breast cancer	3.47e-05	0.000197	CcSEcCtD
Methyldopa—Vomiting—Epirubicin—breast cancer	3.34e-05	0.000189	CcSEcCtD
Methyldopa—Nausea—Methotrexate—breast cancer	3.33e-05	0.000189	CcSEcCtD
Methyldopa—Diarrhoea—Doxorubicin—breast cancer	3.32e-05	0.000189	CcSEcCtD
Methyldopa—Rash—Epirubicin—breast cancer	3.31e-05	0.000188	CcSEcCtD
Methyldopa—Dermatitis—Epirubicin—breast cancer	3.3e-05	0.000188	CcSEcCtD
Methyldopa—Headache—Epirubicin—breast cancer	3.29e-05	0.000187	CcSEcCtD
Methyldopa—Dizziness—Doxorubicin—breast cancer	3.21e-05	0.000182	CcSEcCtD
Methyldopa—Nausea—Epirubicin—breast cancer	3.12e-05	0.000177	CcSEcCtD
Methyldopa—Vomiting—Doxorubicin—breast cancer	3.09e-05	0.000175	CcSEcCtD
Methyldopa—Rash—Doxorubicin—breast cancer	3.06e-05	0.000174	CcSEcCtD
Methyldopa—Dermatitis—Doxorubicin—breast cancer	3.06e-05	0.000174	CcSEcCtD
Methyldopa—Headache—Doxorubicin—breast cancer	3.04e-05	0.000173	CcSEcCtD
Methyldopa—Nausea—Doxorubicin—breast cancer	2.88e-05	0.000164	CcSEcCtD
Methyldopa—ADRA2A—Signaling Pathways—GLI2—breast cancer	1.53e-05	0.000204	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—VCP—breast cancer	1.53e-05	0.000204	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—breast cancer	1.52e-05	0.000203	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—LEPR—breast cancer	1.51e-05	0.000201	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—TGFB1—breast cancer	1.5e-05	0.0002	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—FN1—breast cancer	1.47e-05	0.000196	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CALCA—breast cancer	1.47e-05	0.000196	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—NOS2—breast cancer	1.45e-05	0.000194	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PIK3CG—breast cancer	1.44e-05	0.000192	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CXCR4—breast cancer	1.44e-05	0.000192	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CXCL12—breast cancer	1.44e-05	0.000192	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—AGTR1—breast cancer	1.43e-05	0.000191	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PIK3CD—breast cancer	1.42e-05	0.00019	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PIK3CG—breast cancer	1.41e-05	0.000188	CbGpPWpGaD
Methyldopa—DDC—Metabolism—ALB—breast cancer	1.4e-05	0.000188	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ARHGDIA—breast cancer	1.4e-05	0.000187	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—EGF—breast cancer	1.39e-05	0.000186	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—DPYD—breast cancer	1.37e-05	0.000182	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—MED12—breast cancer	1.37e-05	0.000182	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—FST—breast cancer	1.37e-05	0.000182	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HEY2—breast cancer	1.35e-05	0.00018	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ALDOA—breast cancer	1.34e-05	0.000179	CbGpPWpGaD
Methyldopa—DDC—Metabolism—NOS3—breast cancer	1.34e-05	0.000179	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—RPS6KB2—breast cancer	1.33e-05	0.000178	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—RGS2—breast cancer	1.32e-05	0.000176	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—NCOA3—breast cancer	1.31e-05	0.000174	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCL20—breast cancer	1.3e-05	0.000174	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—AGTR1—breast cancer	1.3e-05	0.000173	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—SLC2A2—breast cancer	1.3e-05	0.000173	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—IGF1—breast cancer	1.29e-05	0.000172	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—AKT2—breast cancer	1.29e-05	0.000172	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—ITPR1—breast cancer	1.28e-05	0.000171	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—PIK3CA—breast cancer	1.28e-05	0.00017	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ABCG2—breast cancer	1.27e-05	0.000169	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CPT1A—breast cancer	1.27e-05	0.000169	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—MTR—breast cancer	1.27e-05	0.000169	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PIK3CD—breast cancer	1.26e-05	0.000169	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TLE3—breast cancer	1.26e-05	0.000168	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—LPAR1—breast cancer	1.26e-05	0.000168	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HEY1—breast cancer	1.25e-05	0.000167	CbGpPWpGaD
Methyldopa—COMT—Metabolism—ALB—breast cancer	1.25e-05	0.000166	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—HPGDS—breast cancer	1.25e-05	0.000166	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PIK3CB—breast cancer	1.24e-05	0.000166	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PIK3CD—breast cancer	1.24e-05	0.000165	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—HBA1—breast cancer	1.24e-05	0.000165	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PTGS2—breast cancer	1.23e-05	0.000164	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—SERPINE1—breast cancer	1.22e-05	0.000164	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—DLL1—breast cancer	1.22e-05	0.000163	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—ALB—breast cancer	1.22e-05	0.000163	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GSTT1—breast cancer	1.21e-05	0.000161	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ACHE—breast cancer	1.21e-05	0.000161	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HIST1H2BC—breast cancer	1.2e-05	0.00016	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HIST1H2BK—breast cancer	1.2e-05	0.00016	CbGpPWpGaD
Methyldopa—COMT—Metabolism—NOS3—breast cancer	1.19e-05	0.000159	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GRB7—breast cancer	1.19e-05	0.000159	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PDE4D—breast cancer	1.19e-05	0.000159	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CSF2—breast cancer	1.19e-05	0.000158	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TAB2—breast cancer	1.17e-05	0.000156	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—NOS3—breast cancer	1.17e-05	0.000156	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—ITPR1—breast cancer	1.17e-05	0.000156	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CNR2—breast cancer	1.16e-05	0.000155	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—CXCL8—breast cancer	1.16e-05	0.000155	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—MMP3—breast cancer	1.16e-05	0.000155	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CYP17A1—breast cancer	1.14e-05	0.000153	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—DKK1—breast cancer	1.13e-05	0.000151	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PTGS1—breast cancer	1.13e-05	0.000151	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ENO1—breast cancer	1.13e-05	0.000151	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—VEGFC—breast cancer	1.12e-05	0.00015	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CYP2D6—breast cancer	1.11e-05	0.000148	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—JAG2—breast cancer	1.11e-05	0.000148	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—RAF1—breast cancer	1.11e-05	0.000148	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PIK3CB—breast cancer	1.1e-05	0.000147	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—WNT1—breast cancer	1.09e-05	0.000146	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PTGS2—breast cancer	1.09e-05	0.000146	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—NCOA2—breast cancer	1.09e-05	0.000145	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PLA2G4A—breast cancer	1.09e-05	0.000145	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PIK3CB—breast cancer	1.08e-05	0.000144	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CSF2—breast cancer	1.08e-05	0.000144	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PTEN—breast cancer	1.07e-05	0.000143	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—FASN—breast cancer	1.06e-05	0.000141	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—BCHE—breast cancer	1.05e-05	0.00014	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—AKT1—breast cancer	1.04e-05	0.000139	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—SLC5A5—breast cancer	1.04e-05	0.000139	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NOTCH4—breast cancer	1.03e-05	0.000138	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GZMB—breast cancer	1.03e-05	0.000137	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—SLC2A1—breast cancer	1e-05	0.000134	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—NQO1—breast cancer	1e-05	0.000134	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—AGTR2—breast cancer	9.98e-06	0.000133	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CXCL2—breast cancer	9.98e-06	0.000133	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—IL2—breast cancer	9.91e-06	0.000132	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PTHLH—breast cancer	9.87e-06	0.000132	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—BMP2—breast cancer	9.87e-06	0.000132	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CYP3A4—breast cancer	9.79e-06	0.000131	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CYP1B1—breast cancer	9.62e-06	0.000128	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—EDNRB—breast cancer	9.56e-06	0.000128	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PTEN—breast cancer	9.52e-06	0.000127	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PGR—breast cancer	9.46e-06	0.000126	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—HSP90AA1—breast cancer	9.44e-06	0.000126	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—THBS1—breast cancer	9.42e-06	0.000126	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—NCOA1—breast cancer	9.18e-06	0.000123	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CYP19A1—breast cancer	9.05e-06	0.000121	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—STK11—breast cancer	9.05e-06	0.000121	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—FLT1—breast cancer	8.99e-06	0.00012	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SQSTM1—breast cancer	8.95e-06	0.000119	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—FGF3—breast cancer	8.95e-06	0.000119	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PIK3CG—breast cancer	8.9e-06	0.000119	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—JAG1—breast cancer	8.83e-06	0.000118	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PARP1—breast cancer	8.8e-06	0.000117	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NOTCH3—breast cancer	8.8e-06	0.000117	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CALCA—breast cancer	8.69e-06	0.000116	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—SRC—breast cancer	8.65e-06	0.000115	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—RPS6—breast cancer	8.59e-06	0.000115	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—FGF4—breast cancer	8.52e-06	0.000114	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CXCL12—breast cancer	8.49e-06	0.000113	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CXCR4—breast cancer	8.49e-06	0.000113	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—VEGFA—breast cancer	8.43e-06	0.000112	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—COMT—breast cancer	8.41e-06	0.000112	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GSTP1—breast cancer	8.37e-06	0.000112	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PAK1—breast cancer	8.33e-06	0.000111	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—HMOX1—breast cancer	8.26e-06	0.00011	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ITPR1—breast cancer	8.24e-06	0.00011	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TCF7L2—breast cancer	8.18e-06	0.000109	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—AKT2—breast cancer	8.15e-06	0.000109	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PIK3CG—breast cancer	8.09e-06	0.000108	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—MAPK3—breast cancer	7.97e-06	0.000106	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ABCB1—breast cancer	7.92e-06	0.000106	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HSP90AA1—breast cancer	7.89e-06	0.000105	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NOTCH2—breast cancer	7.89e-06	0.000105	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PIK3CD—breast cancer	7.83e-06	0.000104	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—TYMS—breast cancer	7.78e-06	0.000104	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—TGFB1—breast cancer	7.73e-06	0.000103	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PLA2G4A—breast cancer	7.69e-06	0.000103	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GSTM1—breast cancer	7.69e-06	0.000103	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—NCOR1—breast cancer	7.69e-06	0.000103	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PRL—breast cancer	7.68e-06	0.000102	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—AGTR1—breast cancer	7.68e-06	0.000102	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ADAM10—breast cancer	7.57e-06	0.000101	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—STK11—breast cancer	7.57e-06	0.000101	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PIK3CA—breast cancer	7.56e-06	0.000101	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PLG—breast cancer	7.48e-06	9.98e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—AKT2—breast cancer	7.4e-06	9.87e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GPX1—breast cancer	7.37e-06	9.83e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—FGF10—breast cancer	7.36e-06	9.82e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CYP1A1—breast cancer	7.29e-06	9.73e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ERCC2—breast cancer	7.23e-06	9.65e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—KRAS—breast cancer	7.16e-06	9.56e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PIK3CD—breast cancer	7.11e-06	9.49e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PDGFA—breast cancer	7.1e-06	9.48e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TGFBR2—breast cancer	7e-06	9.34e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ITPR1—breast cancer	6.89e-06	9.19e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—STAT5A—breast cancer	6.84e-06	9.13e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MMP3—breast cancer	6.84e-06	9.13e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ERBB4—breast cancer	6.84e-06	9.13e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PIK3CB—breast cancer	6.82e-06	9.11e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—MTHFR—breast cancer	6.8e-06	9.07e-05	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PIK3CA—breast cancer	6.71e-06	8.96e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SMAD4—breast cancer	6.63e-06	8.84e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IGF1R—breast cancer	6.59e-06	8.79e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PIK3CA—breast cancer	6.58e-06	8.78e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CXCL8—breast cancer	6.56e-06	8.75e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HES1—breast cancer	6.47e-06	8.64e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PLA2G4A—breast cancer	6.43e-06	8.59e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NCOR1—breast cancer	6.43e-06	8.59e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—TP53—breast cancer	6.37e-06	8.5e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—FGF1—breast cancer	6.36e-06	8.49e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CSF2—breast cancer	6.36e-06	8.49e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—RAF1—breast cancer	6.35e-06	8.47e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NRG1—breast cancer	6.31e-06	8.43e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CAV1—breast cancer	6.27e-06	8.37e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—H2AFX—breast cancer	6.27e-06	8.37e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—IL2—breast cancer	6.27e-06	8.36e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—E2F1—breast cancer	6.22e-06	8.31e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PIK3CB—breast cancer	6.2e-06	8.27e-05	CbGpPWpGaD
Methyldopa—DDC—Metabolism—AKT1—breast cancer	6.18e-06	8.24e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—HRAS—breast cancer	6.09e-06	8.13e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SPP1—breast cancer	5.98e-06	7.98e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CXCL8—breast cancer	5.95e-06	7.95e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ERBB3—breast cancer	5.91e-06	7.89e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—FGFR2—breast cancer	5.91e-06	7.88e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PIK3CG—breast cancer	5.71e-06	7.62e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—IL2—breast cancer	5.69e-06	7.59e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TERT—breast cancer	5.67e-06	7.57e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—FGFR1—breast cancer	5.5e-06	7.35e-05	CbGpPWpGaD
Methyldopa—COMT—Metabolism—AKT1—breast cancer	5.48e-06	7.32e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HIF1A—breast cancer	5.42e-06	7.24e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—AKT1—breast cancer	5.38e-06	7.18e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—LEP—breast cancer	5.29e-06	7.06e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CAV1—breast cancer	5.24e-06	7e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—KDR—breast cancer	5.18e-06	6.92e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ESR1—breast cancer	5.05e-06	6.74e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PIK3CD—breast cancer	5.02e-06	6.7e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—FN1—breast cancer	4.99e-06	6.66e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ALB—breast cancer	4.96e-06	6.62e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NFKBIA—breast cancer	4.93e-06	6.58e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NOTCH1—breast cancer	4.88e-06	6.52e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PIK3CG—breast cancer	4.78e-06	6.38e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—APC—breast cancer	4.78e-06	6.38e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—KIT—breast cancer	4.78e-06	6.38e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—NOS3—breast cancer	4.74e-06	6.33e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—EGF—breast cancer	4.72e-06	6.3e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—MAPK3—breast cancer	4.57e-06	6.11e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—BRAF—breast cancer	4.49e-06	5.99e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PIK3CB—breast cancer	4.38e-06	5.84e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IGF1—breast cancer	4.37e-06	5.84e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—AKT2—breast cancer	4.37e-06	5.83e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—EGFR—breast cancer	4.35e-06	5.81e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PTGS2—breast cancer	4.34e-06	5.79e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PIK3CD—breast cancer	4.2e-06	5.6e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PIK3CA—breast cancer	4.16e-06	5.55e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SERPINE1—breast cancer	4.15e-06	5.54e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—KRAS—breast cancer	4.11e-06	5.49e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NOS3—breast cancer	3.96e-06	5.29e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PTEN—breast cancer	3.78e-06	5.05e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PIK3CA—breast cancer	3.78e-06	5.04e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MDM2—breast cancer	3.76e-06	5.02e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—RAF1—breast cancer	3.75e-06	5e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—RELA—breast cancer	3.73e-06	4.98e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ERBB2—breast cancer	3.71e-06	4.95e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MTOR—breast cancer	3.66e-06	4.89e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PIK3CB—breast cancer	3.66e-06	4.89e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CXCL8—breast cancer	3.52e-06	4.69e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—HRAS—breast cancer	3.49e-06	4.66e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CDKN1B—breast cancer	3.43e-06	4.58e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—AKT1—breast cancer	3.4e-06	4.53e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CASP3—breast cancer	3.37e-06	4.49e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IL2—breast cancer	3.36e-06	4.49e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—IL6—breast cancer	3.34e-06	4.46e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCND1—breast cancer	3.28e-06	4.37e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—JUN—breast cancer	3.27e-06	4.36e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CTNNB1—breast cancer	3.24e-06	4.33e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MMP9—breast cancer	3.18e-06	4.25e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CDKN1A—breast cancer	3.17e-06	4.23e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PTEN—breast cancer	3.16e-06	4.22e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MAPK8—breast cancer	3.09e-06	4.13e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—AKT1—breast cancer	3.09e-06	4.12e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SRC—breast cancer	2.93e-06	3.91e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—VEGFA—breast cancer	2.86e-06	3.81e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—STAT3—breast cancer	2.83e-06	3.78e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MAPK3—breast cancer	2.7e-06	3.61e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PIK3CA—breast cancer	2.67e-06	3.56e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MYC—breast cancer	2.63e-06	3.51e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TGFB1—breast cancer	2.62e-06	3.5e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—EGFR—breast cancer	2.57e-06	3.43e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—KRAS—breast cancer	2.43e-06	3.24e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PIK3CA—breast cancer	2.23e-06	2.98e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—AKT1—breast cancer	2.18e-06	2.91e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TP53—breast cancer	2.16e-06	2.88e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HRAS—breast cancer	2.06e-06	2.76e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IL6—breast cancer	1.98e-06	2.64e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—AKT1—breast cancer	1.82e-06	2.43e-05	CbGpPWpGaD
